Patents by Inventor Adam R. Mezo
Adam R. Mezo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150184142Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.Type: ApplicationFiled: June 7, 2013Publication date: July 2, 2015Applicant: Biogen Idec MA Inc.Inventors: Vu Phong Hong, Adam R. Mezo, Joe Salas, Robert Peters
-
Publication number: 20150139947Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: October 31, 2014Publication date: May 21, 2015Applicant: BIOGEN IDEC HEMOPHILIA INC.Inventors: ROBERT T. PETERS, ADAM R. MEZO, DANIEL S. RIVERA, ALAN J. BITONI, SUSAN C. LOW
-
Patent number: 9012603Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: GrantFiled: December 18, 2009Date of Patent: April 21, 2015Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
-
Patent number: 8932830Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: January 13, 2015Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Patent number: 8906844Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.Type: GrantFiled: August 1, 2008Date of Patent: December 9, 2014Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell
-
Patent number: 8900827Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: December 2, 2014Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Publication number: 20140303084Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.Type: ApplicationFiled: June 9, 2012Publication date: October 9, 2014Applicant: Biogen IDEC MA Inc.Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo
-
Patent number: 8329182Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 23, 2010Date of Patent: December 11, 2012Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 8101186Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: GrantFiled: February 16, 2007Date of Patent: January 24, 2012Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
-
Publication number: 20110230639Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.Type: ApplicationFiled: August 1, 2008Publication date: September 22, 2011Applicant: Syntonix Pharmaceuticals Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell
-
Publication number: 20110182919Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: November 23, 2010Publication date: July 28, 2011Inventors: Robert T. PETERS, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James Stattel, Susan C. Low
-
Publication number: 20110159540Abstract: The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.Type: ApplicationFiled: October 22, 2010Publication date: June 30, 2011Inventors: Adam R. MEZO, Robert T. Peters
-
Publication number: 20110059889Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: ApplicationFiled: December 18, 2009Publication date: March 10, 2011Inventors: ADAM R. MEZO, KEVIN A. MCDONNELL, CRISTINA A. TAN HEHIR, ALFREDO CASTRO
-
Patent number: 7862820Abstract: The invention relates to a chimeric monomer-dimer hybrid protein that comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first polypeptide chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: October 27, 2006Date of Patent: January 4, 2011Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 7820162Abstract: The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.Type: GrantFiled: April 9, 2008Date of Patent: October 26, 2010Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Adam R. Mezo, Robert T. Peters
-
Publication number: 20100048488Abstract: The invention relates to peptides which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.Type: ApplicationFiled: July 31, 2009Publication date: February 25, 2010Inventors: Adam R. Mezo, Kevin A. McDonnell, Ryan Donnelly
-
Publication number: 20080249288Abstract: The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.Type: ApplicationFiled: April 9, 2008Publication date: October 9, 2008Inventors: Adam R. Mezo, Robet T. Peters
-
Patent number: 7404956Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: May 6, 2004Date of Patent: July 29, 2008Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 7381408Abstract: The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule.Type: GrantFiled: May 6, 2004Date of Patent: June 3, 2008Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Adam R. Mezo, Robert T. Peters
-
Patent number: 7348004Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: January 5, 2005Date of Patent: March 25, 2008Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low, James Stattel